APYX COO Roman Shawn David Sells Shares
Roman Shawn David sold 10,533 shares of APYX on June 15, 2026.
Key Points
- Roman Shawn David, COO of APYX, sold 10,533 shares at $4.60 each on June 15, 2026, totaling $48,451.80.
- APYX's stock traded around $4.15 with multiple insider transactions occurring in June 2026.
- Analysts maintain a positive outlook on APYX, with firms like Craig-Hallum and BTIG setting price targets at $6.00.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 15, 2026, Roman Shawn David, the Chief Operating Officer of APYX, sold 10,533 shares of the company at an average price of $4.60 each. This transaction was valued at $48,451.80 and was not part of a pre-planned trading program.
Insider Buying and Selling at Apyx Medical Corporation
Roman Shawn David was active on June 15, 2026, not only selling but also buying 15,000 shares at $3.23 per share. Other insiders, including CEO Charles Goodwin II, were also involved in significant transactions. Goodwin purchased 213,948 shares on June 11, 2026, while Stavros Vizirgianakis and Lawrence Waldman each acquired large share quantities.
Other Institutional Activity in APYX
Several institutional investors adjusted their positions in APYX. Nantahala Capital Management, LLC reduced its holdings by 533,787 shares, now holding 3,440,304 shares worth approximately $12.69 million. Archon Capital Management LLC also trimmed its position, selling 422,303 shares, leaving it with 2,790,923 shares valued at about $10.30 million. Conversely, Royce & Associates LP increased its stake by 168,189 shares, totaling 2,611,224 shares valued at $9.64 million. Vanguard Capital Management LLC made a new investment, acquiring 1,555,272 shares worth $5.74 million.
Apyx Medical Corporation Stock Up 34.7%
APYX shares recently traded around $4.15. The company's stock has been subject to insider and institutional trading activities, reflecting ongoing interest and adjustments in holdings.
Analysts Set New Price Targets
Analyst sentiment towards APYX remains positive. On March 11, 2026, Craig-Hallum maintained its 'buy' rating with a $6.00 price target, while BTIG upgraded its rating to 'buy' with the same target. Earlier, on December 16, 2025, Roth Capital initiated coverage with a 'buy' rating and a $6.00 target.
Bottom Line
The sale of shares by Roman Shawn David is part of a broader series of insider transactions at APYX, underscoring active engagement by company executives. The stock remains a focus for institutional investors, with mixed adjustments in their positions. Analysts continue to support the stock with favorable ratings and price targets, suggesting confidence in its future performance. As always, these insider activities and analyst opinions provide insights but are backward-looking and should be considered with the latest market conditions.
Get Apyx Medical Corporation alerts
New 13F filings, insider trades, and analyst moves on $APYX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.